South Africa: The NHI And The Single Exit Price: Will State Procurement Rules Change?

Last Updated: 25 September 2019
Article by Ian Jacobsberg

South Africa moved a step closer to the introduction of a universal health coverage system with the publication for public comment of the National Health Insurance Bill on 26 July 2019.

There has been much debate around the Bill, with questions raised as to its constitutionality and how long it will take for the programme to become financially and logistically viable (and indeed whether it ever will).

One aspect of the Bill about which little has been written and discussed to date, is the effect that the National Health Insurance Act contemplated by the Bill ("the NHI Act"), if enacted, will have on the State's procurement of medicines and health-related products.

The Medicines and Related Substances Act, 101 of 1965 ("the Medicines Act") defines a medicine as "Any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state, or the symptoms thereof in humans; or restoring, correcting or modifying any somatic or psychic function in humans".

Certain medicines have been designated by the Minister of Health as "Scheduled substances" in terms of section 22A of the Medicines Act. In relation to these, section 22G of the Medicines Act, which was inserted by an amendment in 2002, requires the Minister to make regulations on the introduction of a "transparent pricing system" which must include "a single exit price [which] ... shall be the only price at which manufacturers shall sell medicines and Scheduled substances to any person other than the State".

The Minister of Health published the regulations required in terms of section 22G ("the pricing regulations"), in 2005. The pricing regulations laid down the methodology for the determination of the single exit price ("SEP") in respect of medicines and Scheduled substances. Regulation 6 reinforced section 22A of the Medicines Act, by providing that "a manufacturer, importer, distributor or wholesaler may not charge any fee amount other than the single exit price in respect of the sale of the medicine or scheduled substance to any person other than the State".

The effect of section 22G and regulation 6 is that, while any sale of a medicine or Scheduled substance to a purchaser in the private sector must be at the SEP, the price at which the product is sold to the State is not regulated, and is open to negotiation, subject to the laws relating to procurement of supplies by the State.

The Constitution of the Republic of South Africa, 1996 ("the Constitution") lays down principles governing procurement by the State. Section 217 of the constitution provides that "when an organ of state, or any other institution identified in national legislation, contracts for goods and services, it must do so in accordance with a system which is fair, equitable, transparent, competitive and cost-effective". Section 217(2) allows organs of state or institutions affected by the section to implement policies providing for categories of preference in the allocation of contracts and for the protection or advancement of persons or categories of persons disadvantaged by unfair discrimination. Section 217(3) provides that national legislation must prescribe a framework within which the policy referred to in sub-section (2) must be implemented.

Various pieces of legislation have been enacted to give effect to Section 217. The primary ones amongst these are:

The Public Finance Management Act, 1999 ("PFMA")

The object of the PFMA, as set out in section 2, is "to secure transparency, accountability, and sound management of the revenue, expenditure, assets and liabilities" of the institutions to which [the PFMA] applies". This includes, inter alia, the public entities listed in Schedules 2 and 3 to the PFMA. Section 76(4) of the PFMA authorises the National Treasury to make regulations and issue instructions applicable to all institutions to which the PFMA applies concerning, inter alia, "the determination of a framework for an appropriate procurement and provisioning system which is fair, equitable, transparent, competitive and cost effective".

Treasury Regulations

The Treasury Regulations for departments, trading entities, constitutional institutions and public entities issued in terms of the PFMA ("Treasury Regulations")

Regulation 16 of the Treasury Regulations requires the accounting officer or authority of an institution to which the regulations apply to develop and implement an effective and efficient supply chain management system in the institution for the acquisition of goods and services. The supply chain management system must be "fair, equitable, transparent, competitive and cost effective" and must be consistent with both the Preferential Procurement Policy Framework Act 2000 and the Broad Based Black Economic Empowerment Act 2003.

The Preferential Procurement Policy Framework Act, 2000 ("PPPFA")

Section 2 requires an organ of state to determine its preferential procurement policy and implement within it a preference point system. In terms of the points system, for contracts with a Rand value above a prescribed amount, 90 points must be allocated to the tender amongst those received that is at the lowest price, and a score out of 10 points for the extent to which the tender will allow the organ of state concerned to achieve specific goals, including contracting with persons, or categories of persons, historically disadvantaged by unfair discrimination.

The Preferential Procurement Regulations, 2017 ("Procurement Regulations")

These regulations require that, in evaluating any tender in respect of a contract for the supply of goods and services to a value in excess of R50 million, the organ of state concerned must calculate points out of 90 for price (with the lowest bid scoring 90 points), and points out of 10 to the Broad-based Black Economic Empowerment ("B-BBEE") status of the would-be supplier. In the case of contracts to a value of less than R50 million, the allocations are apportioned in the ratio of 80:20 respectively. If two or more tenderers score an equal number of points, the contract must be awarded to the tenderer who scored the highest points for B-BBEE. Only thereafter may tenders be assessed in regard to compliance with technical specifications (or "functionality").

The NHI Act will provide for the establishment of the National Health Insurance Fund ("the Fund") which, according to the NHI Act, is to be an autonomous public entity, as contained in Schedule 3A to the PFMA. The Fund will aim to achieve sustainable and affordable universal access to quality health care services by, inter alia, "providing for equity and efficiency in funding by pooling of funds and strategic purchasing of ... medicines ..." As a public entity in terms of Schedule 3A to the PFMA, the Fund's procurement of goods and services (including medicines), will be governed by section 217 of the Constitution, the PFMA and the PPFA, and the regulations promulgated under them, referred to above.

Against that background, the NHI Act will bring about two amendments to section 22G(3) of the Medicines Act, which will fundamentally change the way in which medicines are purchased by the public sector. Firstly, the SEP at which medicines are to be sold will be prescribed by the Office of Health Product Procurement, a body within the Fund, to be established in terms of Section 38 of the NHI Act. More significantly, in terms of the amended section 22G(3) of the Medicines Act, the SEP will be the only price at which manufacturers may sell medicines and schedules substances to the Fund or any other person. In other words, the prices of medicines sold to the State, which were previously exempted from the application of the SEP, will now be included, and fixed at the SEP as determined, in the same way as sales to private sector purchasers and end users.

Further, section 3(3) of the NHI Act will provide that if any conflict, relating to the matters dealt with in the NHI Act, arises between the NHI Act and the provisions of any other law, the provisions of the NHI Act will prevail. However, this will not apply where the conflict is between the NHI Act and the Constitution, the PFMA or any Act expressly amending the NHI Act. In addition, section 10(2) of the NHI act will require the Fund to perform its functions "in the most cost-effective and efficient manner possible and in accordance with the values and principles mentioned in section 195 of the Constitution and the provisions of the Public Finance Management Act".

The NHI Act will not bring about any amendments to the PFMA, the PPPFA or any of the regulations promulgated in terms of either of those Acts. However, no indication has been given as to whether the Legislature, when drafting the Bill, and in particular section 3(3) of the NHI Act and the amendments to section 22G(3) of the Medicines Act, considered how effect would be given to the PFMA, section 217 of the Constitution, and in particular the Procurement Regulations, where the price of the products is fixed at the SEP, and will not be open to negotiation or a competitive bidding process. Will the price component in the evaluation of tenders simply fall away? Or will the procurement of medicines by the Fund not be subject to tenders at all? If that is to be the case, a further amendment to the Medicines Act, providing that the provisions of the amended section 22G(3) will prevail over the provisions of the procurement legislation (the PFMA, PPFA and the regulations under them) will probably be necessary. And it will need to be very carefully drafted in order to fall within the criteria laid down by the Constitution regarding procurement by the State. If it is not, a challenge to the constitutionality of the amendment to Section 22G of the Medicines Act may well be on the cards.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions